Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has published a copy of a newspaper publication confirming the dispatch of the notice of its 31st Annual General Meeting and the annual report for the financial year 2025-2026 in Business Standard and Makkal Kural on August 20, 2026.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has informed the Exchange regarding Notice of 31st Annual General Meeting of the Company to be held on September 11, 2026 along with the Annual Report for F.Y 2025-2026.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on August 13, 2026

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Intimation for Book Closure & Cut off Date' for its 31st Annual General Meeting, which will be held on September 11, 2026, through Video Conferencing/OAVM. The Register of Members and Share Transfer Books will be closed from September 5 to September 11, 2026.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has informed the Exchange regarding intimation for the 31st Annual General Meeting of the Company to be held on September 11, 2026. The meeting will be held through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The Register of Members and Share Transfer Books of the company will remain closed from September 5, 2026, to September 11, 2026.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a profit of INR 7.51 lakhs and earnings per equity share of INR 0.03. The company has also announced its 31st Annual General Meeting (AGM) to be held on September 11, 2026.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, along with the outcome of its Board Meeting held on August 11, 2026. The company reported a profit of INR 7.51 lakhs for the quarter, with a basic earnings per share of INR 0.03.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026, confirming the dematerialization of securities and listing on stock exchanges.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has submitted a disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, for the financial year ended on 31st March, 2026.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited announced the retirement of Mr. Navin Kumar as an Independent Director upon completion of his first term, effective June 22, 2026. Consequently, he will also cease to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee. The company has re-constituted these committees to ensure continued compliance with regulatory requirements. This is a routine change due to the expiry of a director's term.